Stockreport

Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC [Yahoo! Finance]

Protara Therapeutics, Inc.  (TARA) 
PDF 100% six-month landmark complete response rate and 80% complete response rate at any time observed in BCG-Unresponsive patients 64% six-month landmark complete respon [Read more]